Core Viewpoint - 康方生物's stock price increased over 5%, reaching a new high of 177.9 HKD, following positive results from its Phase III clinical trial for AK111 in treating ankylosing spondylitis [1] Group 1: Clinical Research Results - 康方生物 announced that its novel humanized anti-IL-17A monoclonal antibody, AK111, achieved positive results in its Phase III clinical trial for active ankylosing spondylitis, meeting all primary efficacy endpoints including ASAS20 and ASAS40, along with several pre-specified secondary endpoints, demonstrating statistical significance and clinical relevance [1] Group 2: Financial Projections - According to Minsheng Securities, 康方生物 is projected to achieve product sales revenue of 2.002 billion CNY in 2024, representing a year-on-year growth of 24.88% [1] - The company's two core products, 卡度尼利单抗 and 依沃西单抗, are expected to be included in the national medical insurance directory by the end of 2024, which will accelerate hospital access and coverage efforts [1] Group 3: Product Development and Commercialization - 康方生物's non-oncology product, 伊努西单抗, has been approved for market launch, and the commercialization process for other non-oncology products, including 依若奇单抗 and 古莫奇单抗, is expected to accelerate as they undergo NDA review [1]